Company intelligence / Profile preview
ViaNautis Bio
Cambridge, England, United Kingdomvianautis.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing VNS002 for Cystic Fibrosis with support from the Cystic Fibrosis Foundation, focusing on identifying optimal formulation candidates for targeted delivery to the conducting airways in the lungs
- Therapeutic areas
- PulmonologyNeurology
- Modalities
- Genetic nanomedicinesnucleic acid therapeutics (pDNA, mRNA, siRNA, ASOs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
LillyCystic Fibrosis Foundation
Beyond the preview
Go deeper on ViaNautis Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViaNautis Bio.